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Employment and social benefits up to 10
years after breast cancer diagnosis:
a population-based study
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and M Schaapveld*,1,3
1Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 2Coronel
Institute of Occupational Health, Academic Medical Center, Amsterdam, The Netherlands; 3Netherlands Comprehensive Cancer
Organisation (IKNL), Utrecht, The Netherlands; 4CoRPS- Centre of Research on Psychology in Somatic Diseases, Department of
Medical and Clinical Psychology, Tilburg University, The Netherlands and 5Department of Surgical Oncology, The Netherlands
Cancer Institute, Amsterdam, The Netherlands
Background: Little is known about employment outcomes after breast cancer (BC) beyond the first years after treatment.
Methods: Employment outcomes were compared with a general population comparison group (N¼ 91 593) up to 10 years after
BC for 26 120 patients, diagnosed before age 55 between 2000–2005, with income and social benefits data from Statistics
Netherlands. Treatment effects were studied in 14 916 patients, with information on BC recurrences and new cancer events.
Results: BC survivors experienced higher risk of losing paid employment (Hazard Ratio (HR): 1.6, 95% Confidence Interval (95% CI)
1.4–1.8) or any work-related event up to 5–7 years (HR 1.5, 95% CI 1.3–1.6) and of receiving disability benefits up to 10 years after
diagnosis (HR 2.0, 95% CI 1.6–2.5), with higher risks for younger patients. Axillary lymph node dissection increased risk of disability
benefits (HR 1.5, 95% CI 1.4–1.7) or losing paid employment (HR 1.3, 95% CI 1.2–1.5) during the first 5 years of follow-up. Risk of
disability benefits was increased among patients receiving mastectomy and radiotherapy (HR 1.2; 95% CI 1.1–1.3) and after
chemotherapy (HR 1.7; 95% CI 1.5–1.9) during the first 5 years after diagnosis.
Conclusions: BC treatment at least partly explains the increased risk of adverse employment outcomes up to 10 years after BC.
Breast cancer (BC) is the most common malignancy among
women in the Western world. About a third of all women
diagnosed with BC is under the age of 55. Prognosis of BC has
improved markedly over the last two decades due to earlier
diagnosis and better treatment, with current 10-year BC survival
approaching 80% for patients diagnosed before age 55 (Verdecchia
et al, 2007).
With employment rates above 60% for women in the Nether-
lands, a large proportion of women diagnosed with BC before age
55 is working. For those confronted with cancer, work offers a
sense of control in insecure times (Lilliehorn et al, 2013; Islam et al,
2014). Moreover, work gives meaning to life, may provide
distraction from the disease and is positively associated with
quality of life (Spelten et al, 2002; Kennedy et al, 2007). Previous
studies have shown that 60%–93% of the BC survivors will
successfully return to work within the first two years after diagnosis
(Bushunow et al, 1995; Satariano and DeLorenze, 1996;
Spelten et al, 2002; Maunsell et al, 2004; Bradley et al, 2005;
Nieuwenhuijsen et al, 2006). Nonetheless, a meta-analysis showed
that BC survivors have a 1.3-fold (95% CI 1.1–1.5) higher risk of
becoming unemployed compared to the general population
(de Boer et al, 2009). A considerable group of BC survivors will
face long term disabilities which may greatly impact on
their financial position and social well-being (de Boer and
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Frings-Dresen, 2009; Hauglann et al, 2012). Even in early stage BC,
the ability to work was negatively influenced at least up to 5 years
after diagnosis (Eaker et al, 2011).
Studies have shown that BC treatment is an important risk
factor for impaired work-ability (Bouknight et al, 2006; Balak et al,
2008; de Boer et al, 2008; Lavigne et al, 2008; Yoon et al, 2008;
Ahn et al, 2009; Fantoni et al, 2010; Hedayati et al, 2012). Chemo-
or hormonal therapy and mastectomy have been associated with
higher risks of unemployment and lower ability to work within the
first years after diagnosis, whereas no such effects were found for
radiotherapy (Drolet et al, 2005a; Balak et al, 2008; Eaker et al,
2011; Lindbohm et al, 2011).
Because in most studies on return to work patients were
followed for only a short time-period, generally less than five years
after treatment, it remains largely unknown what happens after
these first years. With the increasing number of young BC
survivors, it is important to understand the effects of BC and its
treatment on employment beyond the first years after diagnosis.
The objective of this study was to assess the effects of BC and its
treatment on employment and social benefits in a large, unselected
sample of women diagnosed with BC before age 55 up to ten years
after BC diagnosis.
MATERIALS AND METHODS
Study population and data. We composed a cohort comprising
all 26 120 women diagnosed with primary invasive BC as their first
malignancy before the age of 55 years of age in the Netherlands in
the period 2000–2005. Patients were identified through the
Netherlands Cancer Registry (NCR). The cohort contained
information on tumor characteristics and treatment for the
primary BC as well as all subsequent cancers. Details on the
prevailing treatment guidelines in the study period are provided in
Supplementary Appendix 1 (Rutgers et al, 2002). We linked the
NCR cohort with individual social security data, which included
data on individual income, receipt of disability benefits, unemploy-
ment benefits and welfare at Statistics Netherlands, using date of
birth, sex, the date of BC diagnosis and the numerical part of the
patient’s postal code at BC diagnosis. Of all women in the cohort,
23 760 (91%) could be uniquely identified based on these variables.
Statistics Netherlands anonymized the linked cohort and made the
data available to the researchers by secured remote access. The
study protocol was reviewed by the NCR internal review board and
Statistics Netherlands and requirement for individual informed
consent was waived.
General population control sample. We randomly selected
women, frequency-matched on age at diagnosis, from the national
population registry for each of the years 2000 to 2005 as
comparison group. For each BC patient four women were selected.
This general population control sample and the cohort of breast
cancer patients were mutually exclusive. This comparison group
was also linked with social security data at Statistics Netherlands
(N¼ 91 593).
Work-related outcomes
Loss of paid employment. Individual, personal yearly income for
each women was available for 1999–2010 and was based on income
tax data. We defined loss of paid employment as no income from
employment for at least two consecutive years since BC diagnosis,
and only considered women who had had income from employ-
ment before BC.
Disability Benefits. In the Netherlands, during the first two years
of sick leave, the employer continues paying at least 70% of the
employee’s last salary (Supplementary Appendix 2). In principle,
the employee cannot be fired during this period. There is no
national registry that tracks sick days of employees during these
first two years. That means that women on sick leave are
considered to have an income from employment in these first
two years. If a patient is considered unable to work after two years,
she is entitled to a disability pension to compensate for salary-loss
if the salary loss is 435%. However, when recovery from an illness
is considered unlikely, a disability pension can be obtained from 3
weeks after the first sick-day.
Unemployment Benefits and Social Welfare. In the Netherlands,
everyone with paid employment is eligible to receive unemploy-
ment benefits, the duration of which depends on the individual’s
working history. After the maximum duration of unemployment
benefits (3 years and 3 months), local governments are responsible
for the last resort of the Dutch Social Security System: social
welfare. Information received from Statistics Netherlands included
starting date and stop date of unemployment benefits or welfare.
Combined measure of work-related events. Because social
security policies differ between countries, we composed the
measure ‘any work-related event’, reflecting an overall change in
employment status based on either loss of paid employment,
receipt of disability pension, unemployment benefits or welfare.
BC-subsample. Data on subsequent breast cancer events (local,
regional or distal recurrence), collected by the NCR, were available
up to 7 years after BC diagnosis for 14 916 women without distant
metastases at initial BC diagnosis. We studied clinical factors
associated with employment outcomes in this subsample.
Statistical analysis. BC stage was based on clinical and patholo-
gical information. We classified primary treatment as receipt of
chemotherapy (yes/no), hormonal therapy (yes/no), axillary lymph
node dissection (yes/no), and receipt of either lumpectomy with
radiotherapy, mastectomy with radiotherapy, mastectomy without
radiotherapy, or other local therapy. Information on subsequent
cancer events in the subsample was categorized (yes/no) as non-
invasive BC; invasive BC localized; invasive BC metastasized or
non-breast second primary malignancy, other than non-melanoma
skin cancer.
We compared the prevalence of work-related events from one
year prior to diagnosis up to ten years after diagnosis between
patients in the BC cohort and the general population sample, and
estimated cumulative incidence of work-related events, accounting
for death as competing event.
Cox regression was used to compare the risk of work-related
events after BC diagnosis between BC patients and population
controls, accounting for age, individual income before diagnosis
(lowest tertile, middle tertle, highest tertile) and self-employment.
Analysis were adjusted for self-employment as protection through
insurance against loss of income due to unemployment, sickness
and disability is fairly expensive in the Netherlands for self-
employed as this is not organized by the government but largely
left to the private sector. We used the first date of the event in the
analyses. Because of non-proportional hazards over time, analyses
were performed for four separate time intervals: up to 2 years, 2 to
5 years, 5 to 7 years and 7 to 10 years after diagnosis.
We investigated the impact of breast cancer treatment on work-
related outcomes in the BC-subsample using multivariable Cox
regression models with age as timescale, and adjusted for income
before diagnosis, self-employment and new cancer events. New
cancer events were included as time-dependent covariates.
All analyses were performed using STATA statistical software
(Stata 13, StataCorp LP, College Station, TX, USA).
BRITISH JOURNAL OF CANCER Employment 10 years after breast cancer diagnosis
82 www.bjcancer.com | DOI:10.1038/bjc.2015.431
RESULTS
Comparisons with the population control group. Prior to
diagnosis, 69.2% of the BC survivors and 66.6% of the population
controls had paid employment (Figure 1). The cumulative
incidence of paid employment decreased over time more strongly
among BC survivors than among population controls (Po0.001,
Figure 2 and Supplementary Table 1). The cumulative incidence of
loss of paid employment was 51.1% among BC survivors compared
to 46.3% among population controls after 10 years of follow-up.
Among BC survivors, the prevalence of receiving disability
benefits increased strongly in the first two years after diagnosis
from 9.2% prior to BC diagnosis to 25.3% two years later, whereas
among population controls the prevalence of disability benefits
remained fairly stable (7.7% at inclusion and 9.9% at two years;
Figure 1). During follow-up, BC survivors maintained a higher
cumulative incidence of disability benefits (Po0.001, Figure 2 and
Supplementary Table 1). At 10 years of follow-up, the cumulative
incidence of obtaining disability benefits was 32.7% among BC
survivors and 14.1% among population controls.
Before diagnosis, around 3% of both the BC patients and
population controls received unemployment benefits (Figure 1).
The cumulative incidence of unemployment benefits did not differ
between BC survivors and population controls (Figure 2 and
Supplementary Table 1).
Prior to diagnosis 4.6% of the BC patients and 4.3% of
population controls received social welfare. During follow-up BC
patients were at slightly increased risk of receiving welfare
(Po0.001; Figure 2 and Supplementary Table 1), so that after 10
years of follow-up cumulative incidence of women receiving
welfare was 7.9% among BC survivors and 7.4% among the
population controls.
After 10 years of follow-up, 65.5% of the BC patients and 50.6% of
the population controls had experienced at least one of these work-
related events (Po0.001, Figure 2 and Supplementary Table 1).
Table 1 compares risks for work-related events among BC
survivors to risk among population controls. The risk of loss of
personal income was increased in BC survivors up to 5–7 years
after BC diagnosis (HR 0–2 years: 1.3, 95% CI 1.2–1.3; HR 2–5
years: 2.0, 95% CI 1.9–2.1; HR 5–7 years 1.6, 95% CI 1.4–1.8), but
did not differ from that in population controls 7–10 years after BC
diagnosis. Risk was increased to a lesser extent among BC survivors
aged 50–55 years compared to BC patients o50 years at diagnosis
(Pinteractiono0.001). Except for the period 7–10 years after BC
diagnosis, risk of loss of personal income increased with stage
(Supplementary Table 2). The effect of income before diagnosis on
risk of loss of personal income differed between BC patients and
general population controls during the first 5 years of follow-up
(Pinteraction o0.001, Supplementary Table 2). Whereas 0–2 years
after diagnosis risk more strongly decreased with income among
BC patients than controls, at 2–5 years risk was higher for BC
patients in the second or third tertile of income. Self-employed BC
patients had a lower risk of loss of personal income.
BC survivors had a strongly increased risk of obtaining disability
benefits, irrespective of follow-up interval. Whereas among
controls risks increased with age, BC patients had considerably
higher risks at younger ages (Pinteractiono0.001, Table 1 and
Supplementary Table 3). In the first two years post-diagnosis, the
risk of obtaining disability benefits was 13.3-fold increased (95% CI
9.7–18.1) among women o35 years and 7.1-fold increased among
women aged 50–55 years with stage I BC. The risk of obtaining
disability benefits was still 3.3-fold increased among women o35
years and 1.9-fold increased among women aged 45–50 with stage I
BC at 7–10 years of follow-up. Risk of disability benefits increased
with higher BC stage in all intervals. Self-employed BC patients less
often received disability benefits.
BC survivors had a slightly higher risk of obtaining unemploy-
ment benefits in the interval 2–5 years after diagnosis (HR 1.2, 95%
CI 1.1–1.3). Risk did not differ by stage and appeared to be limited
to BC patients in the lower or middle tertile of income
(HR 1.3, 95% CI 1.1–1.5 and HR 1.4, 95% CI 1.2–1.7, respectively;
Supplementary Table 4). BC survivors had a higher risk of
obtaining welfare 0–2 years after diagnosis (HR 0–2 years 1.2, 95%
CI 1.0–1.5, Table 1 and Supplementary Table 5). Beyond 2 years of
follow-up, uptake of welfare benefits did not differ between BC
survivors and population controls.
Overall, BC survivors experienced markedly increased risks of
any work-related event up to 7 years after diagnosis compared to
population controls (HR at 5–7 years: 1.5, 95% CI 1.3–1.6,
Table 1). At 7–10 years of follow-up, risk of a work-related event
was only increased for BC survivors, aged 45–50 at diagnosis (HR
1.4, 95% CI 1.2–1.8), whereas BC survivors aged 50–55 at diagnosis
even had a somewhat lower risk of experiencing a work-related
event (HR 0.8, 95% CI 0.7–1.0). Risk of any work-related event
increased with stage and with tertile of personal income before BC
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Figure 1. Prevalence of work-related outcomes in BC survivors and the general population comparison sample in the year prior to BC diagnosis
and at 2,5,7 and 10 years of follow-up. (A) % women with income from employment. (B) % women with disability benefits. (C) % women with
unemployment benefits. (D) % women on welfare. *Po0.05; **Po0.01; ***Po0.001.
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Effects of treatment: Within cohort comparisons. The sub-
cohort (N¼ 14 916), in which effects of treatment were investi-
gated did not differ from other BC survivors other than by initial
stage (Supplementary Table 7). Treatment differed by age with BC
patients o35 years women more often receiving mastectomy






























































































































Figure 2. Cumulative incidence of losing paid employment and the uptake of social benefits during follow-up in BC patients and general
population controls. (A) Loss of personal income. (B) Disability benefits. (C) Unemployment benefits. (D) Welfare. (E) Any work-related event.
Table 1. Risk (HR) of work-related outcomes after diagnosis: BC survivors compared to general population controls by time since









Loss of personal incomea 1.3 1.2–1.3 2.0 1.9–2.1 1.6 1.4–1.8 1.0 0.9–1.1
Age differences (Pinteraction)
b o0.001 0.001 o0.001 0.020
o35 at diagnosis 1.3 1.1–1.6 2.2 1.7–2.9 2.5 1.4–4.4 2.0#5 1.0–4.3
35–45 at diagnosis 1.5 1.4–1.7 2.3 2.0–2.6 2.9 2.2–3.7 1.2 0.8–1.7
45–50 at diagnosis 1.4 1.2–4.6 2.1 1.9–2.3 2.0 1.7–2.5 1.3 0.9–1.7
50–55 at diagnosis 1.1#1 1.0–1.2 1.7 1.6–1.9 1.2#3 1.0–1.3 0.9#6 0.7–1.0
Disability benefitsa 14.7 13.8–15.8 5.1 4.7–5.6 2.8 2.4–3.4 2.0 1.6–2.5
Age differences (Pinteraction)
b o0.001 o0.001 o0.001 0.023
o35 at diagnosis 22.3 16.5–30.2 12.3 8.1–18.6 5.8 2.6–12.8 4.0 1.7–9.7
35–45 at diagnosis 18.5 16.2–21.0 7.0 5.9–8.3 4.6 3.5–6.1 2.6 1.8–3.8
45–50 at diagnosis 16.0 14.2–18.1 4.6 3.4–5.4 2.9 2.1–3.8 2.1 1.4–2.9
50–55 at diagnosis 11.1 10.0–12.4 3.8 3.2–4.4 1.4#4 1.0–2.0 1.2 0.8–1.9
Unemployment benefitsa 1.0 0.9–1.1 1.2 1.1–1.3 1.0 0.8–1.1 0.8#7 0.7–1.0
Age differences (Pinteraction)
b 0.28 0.88 0.06 0.32
Welfare pensiona 1.2#2 1.0–1.5 1.1 0.9–1.4 0.8 0.6–1.2 0.9 0.7–1.3
Age differences (Pinteraction)
b 0.31 0.45 0.83 0.64
Any work-related eventa 3.8 3.7–4.0 1.6 1.5–1.7 1.5 1.3–1.6 1.0 0.9–1.2
Age differences (Pinteraction)
b o0.001 o0.001 o0.001 o0.001
o35 at diagnosis 3.6 3.0–4.2 1.7 1.3–2.2 2.4 1.5–3.8 1.1 0.5–2.2
35–45 at diagnosis 4.3 4.0–4.7 2.1 1.8–2.3 2.3 1.9–2.7 1.2 0.9–1.6
45–50 at diagnosis 4.4 4.1–4.8 1.7 1.5–1.9 1.6 1.3–1.9 1.4 1.2–1.8
50–55 at diagnosis 3.1 2.9–3.4 1.4 1.2–1.5 1.1 0.9–1.2 0.8#8 0.7–1.0
Abbreviations: HR¼Hazard ratio; 95% CI¼ 95% confidence interval. Differences in HRs of the outcome measures between follow-up intervals were all significant (Po0.001 loss of personal
income, disability benefits, unemployment benefits, any work-related event and Po0.005 for welfare pension). #1P¼ 0.34; #2P¼ 0.034; #3P¼ 0.018; #4P¼ 0.057; #5P¼ 0.063; #6P¼ 0.064;
#7P¼ 0.035; #8P¼ 0.044.
aadjusted for age, income before diagnosis and being self-employed (no interactions).
badjusted for age, income before diagnosis and being self-employed (evaluation of interaction for age, averaged effect over stage).
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than BC patients aged 50–55 years (Supplementary Table 8).
Compared to women treated with lumpectomy followed by
radiotherapy and adjusted for age, time since diagnosis, individual
income before diagnosis, self-employment and subsequent cancer
events, women treated with mastectomy followed by radiotherapy
had a higher risk of obtaining disability benefits (HR 1.2, 95% CI
1.1–1.3) or any work-related event (HR 1.1, 95% CI 1.0–1.2)
(Table 2). Axillary lymph node dissection was associated with
increased risk of loss of personal income up to 5 years after
diagnosis (HR 1.3, 95% CI 1.2–1.5) but not thereafter, as well as
with obtaining disability benefits (HR 1.5, 95% CI 1.4–1.7) and any
work-related event (HR 1.4, 95% CI 1.3–1.5).
Chemotherapy was associated with increased risk of obtaining
disability benefits (HR 1.7, 95% CI 1.5–1.9) and any work-related
event (HR 1.4, 95% CI 1.2–1.5) during the first 5 years after
diagnosis. Women treated with mastectomy followed by radio-
therapy had, on the other hand, a lower risk of obtaining
unemployment benefits compared to women treated with
lumpectomy followed by radiotherapy (HR 0.8, 95% CI 0.6–1.0).
Women treated with hormonal therapy had lower risk of any
work-related event than women not treated with hormonal therapy
(HR 0.9, 95% CI 0.8–1.0).
DISCUSSION
This nationwide population-based study showed that BC survivors
experienced increased risk of obtaining disability benefits up to ten
years after diagnosis, increased risk of loss of paid employment up
to 7 years after diagnosis and increased risk of obtaining
unemployment benefits up to five years after diagnosis. The
magnitude of risk of adverse work-related outcomes differed by
age, with women diagnosed before 35 years of age having the
highest risk of obtaining disability benefits and women aged 35–45
having the highest risk of obtaining unemployment benefits. BC
survivors treated with mastectomy followed by radiotherapy,
chemotherapy or axillary lymph node dissection experienced
higher risk of adverse employment outcomes, other than
unemployment.
Previously de Boer et al (2009) found a 1.3-fold increased risk of
unemployment among BC survivors. We found a smaller, 1.2-fold
increased risk of obtaining unemployment benefits, limited to the
period 2–5 years after diagnosis. This may be explained by
differences in the definition of unemployment in both studies and
the fact that the meta-analysis by de Boer and colleagues included
studies from various countries with a diversity of social security
systems. While in the meta-analysis various work-related outcomes
such as sick leave and disability benefits were combined into one
measure ‘not being employed’, in contrast our study only
considered women who actually received unemployment benefits.
Our results for any work-related event, which probably better
resembles the outcome used in the meta-analyses, however showed
much higher risks.
In the first two years after BC diagnosis we found no increased
risks of receiving unemployment benefits, which may reflect Dutch
regulations (Sharp and Timmons, 2011; Gimeno et al, 2014).
However, beyond 2 years after diagnosis BC survivors, and
particularly those aged 35–45 at diagnosis, do appear to experience
increased risk of losing their job. Life course specific factors, such
as having young children at the time of BC diagnosis, may at least
partly explain these differences in risk with age.
Although several previous studies observed higher risks of
adverse employment outcomes with older age at diagnosis (Drolet
et al, 2005a; Carlsen et al, 2008; Hassett et al, 2009; Islam et al,
2014) we found, in general, higher risks among women younger
than 45 years at diagnosis. Although it may be expected that a
serious illness such as breast cancer is associated with adverse
employment outcomes, even 7–10 years after diagnosis the risk of
obtaining disability benefits remains increased, particularly among
younger BC patients. BC and its treatment is often more aggressive
at younger ages and young BC survivors may therefore also face
more severe long-term adverse effects, including those which are
work-related (Bloom et al, 2013). In addition, age-differences
regarding survivorship issues have been reported. For instance,
Ganz and colleagues found that younger BC survivors reported
more impact of cancer on a range of life plans and activities,
including working life, 5–10 years after diagnosis, compared to
older women (Ganz et al, 2002). It is therefore important to further
investigate the needs of women in specific age groups to enhance
sustainable return to work and to prevent these women from
dropping out of the labor market long after their treatment has
ended.
In line with previous studies (Drolet et al, 2005b; Balak et al,
2008; Ahn et al, 2009; Johnsson et al, 2009; Hassett et al, 2009;
Fantoni et al, 2010; Johnsson et al, 2010; Blinder et al, 2012;
Hedayati et al, 2012; Jagsi et al, 2014), we found that patients
treated with mastectomy followed by radiotherapy, axillary lymph
Table 2. Associations of treatment for primary BC with work-related outcomes after BC in the BC subsample
Loss of personal income Disability benefits Unemployment benefits Any work-related event
Tot/event* HR** 95%CI Tot/event HR 95%CI Tot/event HR 95%CI Tot/event HR 95%CI
Surgery
Lumpectomy & RT*** 5920/1275 1.0 Ref 6997/1278 1.0 Ref 7216/553 1.0 Ref 4841/1794 1.0 Ref
Mastectomy 2965/652 1.0 0.9–1.1 3653/717 1.0 0.9–1.1 3814/267 0.9 0.8–1.1 2425/971 1.0#6 1.0–1.1
Mastectomy & RT 1940/474 1.1#1 1.0–1.3 2384/701 1.2 1.1–1.3 2488/130 0.8#4 0.6–1.0 1582/754 1.1#7 1.0–1.2
Axillary lymph node dissection 6463/1535 7930/1975 1.5 1.4–1.7 8242/557 1.1#5 1.0–1.3 5315/2364
o5 years after diagnosis 1.3 1.2–1.5 1.4 1.3–1.5
45 years after diagnosis 0.8#2 0.6–1.0 1.0 0.8–1.3
Chemotherapy 7019/1560 1.0 0.9–1.2 8601/582 0.9 0.8–1.1 5745/2466
o5 years after diagnosis 1.7 1.5–1.9 1.4 1.2–1.5
45 years after diagnosis 1.0 0.7–1.3 1.0 0.8–1.2
Hormone therapy 4899/1132 1.0 0.9–1.1 5839/1362 0.9#3 0.9–1.0 6067/403 0.9 0.8–1.1 4019/1663 0.9#8 0.8–1.0
Abbreviations: *Tot¼ total; **HR¼ hazard ratio; 95% CI ¼ 95% confidence interval; ***RT¼ radiotherapy. Note1: Model adjusted for age (time scale, continuous), time since diagnosis (0–2,
2–5, 5–7 and X7 years), self-employment, individual income before diagnosis (tertiles) and new (breast) cancer events (time-varying). Data for subsequent breast events (loco-regional
recurrence and/or distant metastases) were available up to 6 years after diagnosis, data for new cancer events (including newly diagnosed ipsilateral or contralateral breast cancer) up to 10 year
after diagnosis. #1P¼ 0.051; #2P¼ 0.10; #3P¼ 0.12; #4P¼ 0.011; #5P¼ 0.15; #6P¼ 0.47; #7P¼ 0.018.; #8P¼ 0.021.
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node dissection or chemotherapy had higher risk of various work-
related events, even after accounting for new cancer events.
Mastectomy followed by radiotherapy and axillary lymph node
dissection may influence working life long after treatment due to
increased risk of chronic pain and lymphedema (Nesvold et al,
2010; Eaker et al, 2011). Although many side effects of
chemotherapy are temporary (Eaker et al, 2011), studies have
found that chemotherapy may impact on cognitive functioning
(de Ruiter et al, 2011) and fatigue (Reinertsen et al, 2010) up to 10
years after diagnosis. Both cognitive functioning and fatigue have
been associated with impaired work functioning (Islam et al, 2014).
Further research is needed on underlying mechanisms causing
long-term treatment side effects and their impact on employment.
In contrast to previous studies (Eaker et al, 2011; Islam et al,
2014), we found no increased risk of adverse work-related events
after hormonal therapy. Most of these studies only assessed the
effects on (short-term) sickness absence whereas in our study
women were followed up to ten years after BC diagnosis. Women
with hormone sensitive tumors have better overall prognoses and
may less often need to obtain disability benefits.
As we accounted for new (breast) cancer events and the
treatment effects appeared independent of subsequent (breast)
cancer events, the effects of treatment we found do not merely
reflect the underlying differences in stage.
Strengths and limitations. Some limitations need to be considered
when interpreting the results. First of all, we acknowledge that we
present many significance tests and therefore caution against over-
interpretation of our findings, especially when based on
P-values 40.001. Furthermore, our study does reflect the Dutch
social benefits and welfare system and therefore our results may not
be fully generalizable to other countries in the European Union,
let alone farther afield. In general, the structure of social security
legislation in the Netherlands does provide reasonable protection to
Dutch employees which may be less so elsewhere. The vulnerable
position of young women has, however, been found in other
countries as well, which may indicate that BC survivors share risk
factors transcending mere effects of social security systems.
Furthermore, our results need to be interpreted within the context
of a continuously changing landscape, due to changes in both BC
treatment and work-related legislation. Further research could focus
on the impact of legislation on adverse work-related outcomes in
order to improve the employment position of BC survivors.
Data on subsequent cancer events were only available for a part
of our BC cohort. However, again our data did not provide any
indication that the sub-cohort differed from other BC survivors
other than by initial stage (women with tumor stage IV were not
followed-up by the NCR). Furthermore, our study lacked
information on reasons for losing paid employment and we have
no information on, for instance, perceived work ability of the
women in our study. In order to enhance sustainable work among
BC survivors, more detailed information from BC survivors and
other stakeholders, such as their employer and their colleagues is
needed. Therefore the present study was followed-up by a survey
study in order to gain more insight in factors hampering or
facilitating employment after BC.
Nonetheless, this is one among few studies to evaluate adverse
work-related events in a large, population-based cohort of fairly
recently treated BC survivors beyond the first 5 years after
initial BC treatment, with good quality data on initial treatment
(Carlsen et al, 2008; Hauglann et al, 2012). We used highly reliable,
high quality social security data from Dutch government institu-
tions to identify identified work-related events using, instead
of relying on self-reported outcomes, resulting in unbiased
information. Furthermore, this study took new BC events into
account when evaluating the effect of BC and its treatment on
work-related outcomes.
Since many BC survivors will experience work-related problems
and considering the fact that work is an important aspect of
rehabilitation, work and return to work should be a standard topic to
discuss after completion of treatment. Oncologists should timely refer
patients, whenever patients may need support with work reintegra-
tion. In the Netherlands, several innovative rehabilitation programs
are being initiated to improve the occupational rehabilitation of breast
cancer patients, including support of occupational physicians with a
specialised training in oncological issues (Zaman et al, 2015) and
hospital-based work support interventions (Tamminga et al, 2013).
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